Continuous infusion followed by subcutaneous injection of campath-1H [alemtuzumab] plus rituximab in the treatment of CD52- and CD20-positive refractory or relapsed chronic lymphoid disorders.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Alemtuzumab (Primary) ; Rituximab
Indications Large granular lymphocytic leukaemia; Lymphoproliferative disorders; Richter's syndrome
Focus Therapeutic Use

24 Feb 2011 Actual end date (1 Aug 2007) added as reported by ClinicalTrials.gov.
24 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
16 Oct 2006 Status change

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com